Gyejigachulbutang (Gui-Zhi-Jia-Shu-Fu-Tang, Keishikajutsubuto, TJ-18) in Degenerative Knee Osteoarthritis Patients: Lessons and Responders from a Multicenter Randomized Placebo-Controlled Double-Blind Clinical Trial

Table 3

Demographics and baseline health characteristics (N = 80).

Characteristics		GCB group^†	Placebo group^†	value^a
Gender	Male	11 (27.50%)	9 (22.50%)	0.7968
	Female	29 (77.50%)	31 (77.50%)
Age (year)		66.53 (63.95, 69.10)	65.38 (62.51, 68.24)	0.5472
Height (cm)		157.46 (155.15, 159.77)	158.00 (155.14, 160.87)	0.7652
Weight (kg)		62.33 (59.59, 65.07)	62.36 (59.37, 65.35)	0.9871
BMI (kg/m^2)		25.11 (24.23, 25.99)	24.94 (24.00, 25.87)	0.7860
Job	Yes	33 (82.50%)	32 (80.00%)	0.9999
	No	7 (17.50%)	8 (20.00%)
Exercise	Yes	28 (70.00%)	20 (50.00%)	0.1095
	No	12 (30.00%)	20 (50.00%)
Exercise time (minute/week)		273.00 (213.50, 332.6)	207.50 (138.00, 277.00)	0.1464
X-ray
K-L grade 2		31 (77.50%)	28 (70.00%)	0.5600
K-L grade 3		7 (17.50%)	11 (27.50%)
K-L grade 4		2 (5.00%)	1 (2.50%)
Morbidity period (month)		97.43 (74.19, 120.66)	91.35 (71.51, 111.19)	0.6887
Treatment expectancy		17.08 (16.12, 18.03)	17.00 (15.82, 18.18)	0.9207

^†Data expressed either n (%) or 95% confidence interval. ^a value are from the independent two-sample t-test for continuous variables and from either the chi-squared test or Fisher’s exact test for categorical variables. GCB, Gyejigachulbutang; BMI, body mass index; K-L grade, Kellgren–Lawrence grade.